JCO Precision Oncology Conversations

In this episode of JCO Precision Oncology Article Insights, host Jiasen He summarizes the article, "Beyond the Brain: Circulating Tumor Cells as a Tool for Diagnosis and Monitoring," by Lessi and colleagues.

LINK TO FULL TRANSCRIPT

JCO PO Editor-in-Chief Emeritus Dr. James Ford and Founding PI, ASCO TAPUR Study, Dr. Richard Schilsky discuss the 10-year anniversary of the Targeted Agent and Profiling Utilization Registry (TAPUR)™ Study and its relationship with the journal. Host Dr. Rafeh Naqash and guests discuss the inception/history of the TAPUR study, its future, and advances in precision medicine over the past decade.

LINK TO FULL TRANSCRIPT

In this JCO PO Article Insights episode, host Carolyn Lineen summarizes the article, "Breast Neuroendocrine Carcinoma: Molecular Insights Beyond Histology" by Schwartz and colleagues.

LINK TO FULL TRANSCRIPT

JCO PO authors Dr. James Hadfield, Dr. Grace Yiqing Zhao, and Dr. Julia Elvin at AstraZeneca share insights into the JCO PO article, "Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals?" Host Dr. Rafeh Naqash and guests discuss emerging evidence that cfDNA methylation profiling provides sensitive, specific signals of tissue injury across multiple organs and clinical contexts.

LINK TO FULL TRANSCRIPT

In this episode of JCO PO: Article Insights, host Jiasen He summarizes the article, "Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study," by Roberts and colleagues.

LINK TO FULL TRANSCRIPT

JCO PO author Dr. Emily Miao at Mass General Brigham Cancer Institute shares insights into the JCO PO article, "Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK-Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers." Host Dr. Rafeh Naqash and Dr. Miao discuss the clinicogenomic characteristics and treatment outcomes of patients with ALK+ squamous and adenosquamous lung cancers and how these outcomes compare to those of patients with ALK+ adenocarcinoma treated with first-line alectinib.

LINK TO FULL TRANSCRIPT

In this JCO PO Article Insights episode, host Carolyn Lineen summarizes the article, "Genomics of MTAP Loss in >500,000 Solid Tumor Specimens Profiled Using Comprehensive Genomic Profiling Platforms" by Dean C. Pavlick and colleagues.

LINK TO FULL TRANSCRIPT

JCO PO authors Dr. Matthew Campbell and Dr. Mohammad Moussa at The University of Texas MD Anderson Cancer Center and Baylor College of Medicine, Houston, Texas, share insights into their article, "Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability." Host Dr. Rafeh Naqash and Drs. Campbell and Moussa discuss how the study findings suggest that dMMR/MSI-H may serve as a biomarker of sensitivity to single-agent ICIs in advanced UTUC.

LINK TO FULL TRANSCRIPT

In this JCO PO Article Insights episode, host Jordan Goldstein summarizes the article, "EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer" byTakahashi, et al.

LINK TO FULL TRANSCRIPT

JCO PO author Dr. Tejas Patil at University of Colorado Cancer Center shares insights into the JCO PO article, "CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions". Host Dr. Rafeh Naqash and Dr. Patil discuss the anti-tumor activity and safety data of seribantumab from the CRESTONE study (NCT04383210).

LINK TO FULL TRANSCRIPT